Piper Jaffray analyst Christopher Raymond continues to like the setup for shares of Regeneron Pharmaceuticals following the company's "strong" Q2 results. With both Eylea and Dupixent driving the upside in the quarter, the Sanofi antibody collaboration now profitable, and numerous pipeline events in the coming quarters, there's "lots to like with this name," Raymond tells investors in a post-earnings research note. He views concerns over the macro environment and brolucizumab competition as overblown and keeps an Overweight rating on Regeneron with a $435 price target.